An ongoing phase I/IIa study is investigating the combination of AFM24 with atezolizumab, a PD-L1 inhibitor, in patients with advanced or metastatic EGFR wild-type (EGFR-WT) NSCLC who have progressed on chemotherapy and ICI [30]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.